[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-337504-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-337504-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","genetic-basis-of-breast-and-ovarian-cancer-approaches-and-lessons-learnt-from-three-decades-of-inherited-predisposition-testing","Genetic Basis of Breast and Ovarian Cancer - Approaches and Lessons Learnt from Three Decades of Inherited Predisposition Testing","","Germline variants in BRCA1 and BRCA2 drive hereditary breast and ovarian cancer (HBOC) syndrome, predisposing to breast, ovarian, fallopian tube, and peritoneal malignancies with elevated genomic aberrations and unfavorable outcomes. BRCA1/2 participate in genetic integrity through homologous recombination (HR) DNA repair, a high-fidelity pathway for double-strand break repair. HR impairment is also a therapeutic vulnerability exploited by poly(ADP-ribose) polymerase (PARP) inhibitors. This review outlines HR roles in PARP inhibitor sensitivity, summarizes hereditary gene architectures across penetrance levels using germline and somatic variation, and addresses genomic complexity via polygenic risk scores to optimize prevention and therapy.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/genetic-basis-of-breast-and-ovarian-cancer-approaches-and-lessons-learnt-from-three-decades-of-inherited-predisposition-testing/337504/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/genetic-basis-of-breast-and-ovarian-cancer-approaches-and-lessons-learnt-from-three-decades-of-inherited-predisposition-testing/337504.png","ImageObject",300,407,{"name":42,"@type":43},"Anda","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-28","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",16,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"How do BRCA1 and BRCA2 variants contribute to hereditary breast and ovarian cancer risk?","Question",{"text":63,"@type":64},"They cause the HBOC syndrome, increasing susceptibility to breast, ovarian, fallopian tube, and peritoneal cancers. The cancers are associated with elevated genomic aberrations and poor prognoses.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What biological role of BRCA1/2 is central to this review’s therapeutic focus?",{"text":68,"@type":64},"BRCA1 and BRCA2 are involved in homologous recombination (HR) DNA repair. HR impairment becomes a target for therapy using PARP inhibitors.",{"name":70,"@type":61,"acceptedAnswer":71},"Which genetic variation types and complexity measures are discussed to improve prevention and treatment strategies?",{"text":72,"@type":64},"The review considers both germline and somatic variations and discusses higher complexity approaches such as polygenic risk scores. These aim to optimize therapeutic and preventive strategies for breast and ovarian cancer.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},337504,1790158827,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":140,"language":141,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":12,"update_tm":145,"read_time":146,"preview_page_count":33,"preview_urls":147},962075006959,"https://ap-avatar.wpscdn.com/avatar/e0002397efbe92a78e?_k=1776741047341049297","Review  \nGenetic Basis of Breast and Ovarian Cancer: Approaches and Lessons Learnt from Three Decades of Inherited Predisposition Testing  \nValeria Barili 1,†, Enrico Ambrosini 2,†, Beatrice Bortesi 3, Roberta Minari 3, Erika De Sensi 1,  \nIlenia Rita Cannizzaro 1, Antonietta Taiani 1, Maria Michiara 3,4, Angelica Sikokis 3,4, Daniela Boggiani 3,4, Chiara Tommasi 1,3,4, Olga Serra 3,4, Francesco Bonatti 3, Alessia Adorni 3, Anita Luberto 1, Patrizia Caggiati 2, Davide Martorana 2, Vera Uliana 2, Antonio Percesepe 1,2, *, Antonino Musolino 1,3,4, *  \nand Benedetta Pellegrino 3,4  \nCitation: Barili, V.; Ambrosini, E.; Bortesi, B.; Minari, R.; De Sensi, E.; Cannizzaro, I.R.; Taiani, A.; Michiara, M.; Sikokis, A.; Boggiani, D.; et al. Genetic Basis of Breast and Ovarian Cancer: Approaches and Lessons Learnt from Three Decades of Inherited Predisposition Testing. Genes 2024, 15, 219. [https://doi.org/](https://doi.org/)[ ](https://doi.org/)[10.3390/genes15020219](10.3390/genes15020219)  \nAcademic Editor: Shinya Nishio  \nReceived: 30 December 2023  \nRevised: 2 February 2024  \nAccepted: 5 February 2024  \nPublished: 8 February 2024  \nCopyright: © 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://](https://)[ ](https://)[creativecommons.org/licenses/by/](creativecommons.org/licenses/by/)[ ](creativecommons.org/licenses/by/)[4.0/](4.0/)) .  \n1 Department of Medicine and Surgery, University of Parma, 43126 Parma, Italy  \n2 Medical Genetics, University Hospital of Parma, 43126 Parma, Italy  \n3 Medical Oncology Unit, University Hospital of Parma, 43126 Parma, Italy  \n4 Breast Unit, University Hospital of Parma, 43126 Parma, Italy  \n* Correspondence: [antonio.percesepe@unipr.it](antonio.percesepe@unipr.it) (A.P.); [antonino.musolino@unipr.it](antonino.musolino@unipr.it) (A.M.)† These authors contributed equally to this work.  \nAbstract: Germline variants occurring in BRCA1 and BRCA2 give rise to hereditary breast and ovarian cancer (HBOC) syndrome, predisposing to breast, ovarian, fallopian tube, and peritoneal cancers marked by elevated incidences of genomic aberrations that correspond to poor prognoses. These genes are in fact involved in genetic integrity, particularly in the process of homologous recombination (HR) DNA repair, a high-fidelity repair system for mending DNA double-strand breaks. In addition to its implication in HBOC pathogenesis, the impairment of HR has become a prime target for therapeutic intervention utilizing poly (ADP-ribose) polymerase (PARP) inhibitors. In the present review, we introduce the molecular roles of HR orchestrated by BRCA1 and BRCA2 within the framework of sensitivity to PARP inhibitors. We examine the genetic architecture underneath breast and ovarian cancer ranging from high-and mid-to low-penetrant predisposing genes and taking into account both germline and somatic variations. Finally, we consider higher levels of complexity of the genomic landscape such as polygenic risk scores and other approaches aiming to optimize therapeutic and preventive strategies for breast and ovarian cancer.  \nKeywords: hereditary breast and ovarian cancer (HBOC) syndrome; BRCA1 and BRCA2; homologous recombination deficiency (HRD); poly (ADP-ribose) polymerase (PARP) inhibitors  \n1. Introduction  \nBreast cancer is the most prevalent type of cancer in women worldwide and the existence of a familial predisposition has been known for at least 150 years [1] . The cosegregation of familial ovarian and breast cancer was described in the second part of the 20th century. In 1994, through extensive research on families with a history of early-onset breast and/or ovarian cancer, the discovery of the connection between BRCA1 and BRCA2 genes and the development of cancer risk was made [2,3] . Shortly after, BRCA1/2 screening became available for clinical use with an immediate effect ","cbCaioqfLhR8p2ZG","https://ap.wps.com/l/cbCaioqfLhR8p2ZG","pdf",2074771,31,"English","# Abstract\n## Keywords\n## Introduction","[{\"question\":\"How do BRCA1 and BRCA2 variants contribute to hereditary breast and ovarian cancer risk?\",\"answer\":\"They cause the HBOC syndrome, increasing susceptibility to breast, ovarian, fallopian tube, and peritoneal cancers. The cancers are associated with elevated genomic aberrations and poor prognoses.\"},{\"question\":\"What biological role of BRCA1/2 is central to this review’s therapeutic focus?\",\"answer\":\"BRCA1 and BRCA2 are involved in homologous recombination (HR) DNA repair. HR impairment becomes a target for therapy using PARP inhibitors.\"},{\"question\":\"Which genetic variation types and complexity measures are discussed to improve prevention and treatment strategies?\",\"answer\":\"The review considers both germline and somatic variations and discusses higher complexity approaches such as polygenic risk scores. These aim to optimize therapeutic and preventive strategies for breast and ovarian cancer.\"}]","Genetic Basis of Breast and Ovarian Cancer - Approaches and Lessons Learnt from Three Decades of Inherited Predisposition Testing | PDF",1790019352,78,[148,152,156,160],{"page_no":22,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c996cf0efc742cbaf2a7e71306072b2d.webp",983,1390,{"page_no":26,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/70fe63c3214b49015b7515bec968e4bd.webp",982,1388,{"page_no":30,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c3f3237e0e47511fabb9a8f0fb9b2473.webp",981,1387,{"page_no":33,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4aef2b87ddd951bdb09041d4ac3df254.webp",980,1385]